Related Experiment Video
Updated: Sep 10, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg
Simon J Hume1,2,3, Samuel Hall1,2, Gareth Burns4
1St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Insights
Discontinuing nucleos(t)ide analogues (NAs) can lead to functional cure (HBsAg loss) in chronic hepatitis B (CHB) patients. Lower end-of-treatment HBsAg levels predict successful HBsAg loss, though flares may occur.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Nucleos(t)ide analogues (NAs) are standard treatment for chronic hepatitis B (CHB).
- Discontinuation of NAs may offer a chance for functional cure, defined as hepatitis B surface antigen (HBsAg) loss.
- Predicting successful NA discontinuation and functional cure is crucial for patient management.
Purpose of the Study:
- To evaluate the long-term rates of HBsAg loss after stopping NAs in CHB patients.
- To identify predictors of HBsAg loss and assess safety outcomes, including hepatitis flares and hepatocellular carcinoma (HCC).
Main Methods:
- A real-world extension study followed 97 participants with HBeAg-negative CHB without cirrhosis after NA discontinuation.
- Efficacy outcomes (HBsAg loss/decline) and safety outcomes (hepatitis flares, HCC) were monitored over a median of 7 years.
- Statistical analyses identified predictors of HBsAg loss.
Main Results:
- Cumulative incidence of HBsAg loss reached 22% at 9 years post-NA cessation.
- Lower end-of-treatment (EOT) HBsAg levels (≤10 IU/mL) predicted early HBsAg loss without flares.
- Higher EOT HBsAg levels (≥10 IU/mL) were associated with later HBsAg loss, sometimes following ALT flares. Older age and peak off-treatment HBV DNA also predicted HBsAg loss.
- No hepatic decompensation, transplantation, or death occurred. HCC incidence was 4.4/1000 person-years.
Conclusions:
- Functional cure rates increase over long-term follow-up but remain low.
- EOT HBsAg level is a strong predictor of HBsAg loss likelihood and timing.
- ALT flares are linked to HBsAg decline and can influence the timing of HBsAg loss.
Background And Aims:
Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective cohort.
Methods:
This real-world extension study followed participants from a prospective trial of NA discontinuation. All patients had HBeAg-negative CHB without cirrhosis. Efficacy outcomes (including HBsAg loss and decline) and safety outcomes [including hepatitis flare and hepatocellular carcinoma (HCC)] were evaluated.
Results:
Amongst 97 participants (85% Asian), with a median follow-up of 7 years, the cumulative incidence of HBsAg loss was 10%, 13% and 22% at 5, 7 and 9 years after stopping NA. HBsAg loss was associated with a lower end-of-treatment (EOT) HBsAg level (HR = 0.28, p < 0.001), older age (HR = 1.14, p = 0.005) and peak off-treatment HBV DNA level (OR = 0.50, p = 0.002). Participants with EOT HBsAg level ≤ 10 IU/mL experienced early HBsAg loss (< 96 weeks) without ALT flares whilst those with EOT HBsAg level ≥ 10 IU/mL experienced late (≥ 96 weeks) HBsAg loss, often following ALT flares (5/8 cases). No cases of hepatic decompensation, liver transplantation or death occurred. Median liver stiffness did not increase. HCC was diagnosed in three individuals (4.4/1000 person-years).
Conclusion:
The rate of functional cure increased during long-term follow-up but remained low. EOT HBsAg strongly predicted the likelihood and timing of HBsAg loss. ALT flares were associated with HBsAg decline, and in some cases, with delayed HBsAg loss.
Trial Registration:
The clinical study was supported by the National Health and Medical Research Council of the study clinical trial ID is NCT02581033.
Related Concept Videos
Assumptions of Survival Analysis
Longitudinal Research
Longitudinal Studies
Retrovirus Life Cycles

